Nav: Home

Antihypertensive medications and fracture risk: Is there an association?

November 21, 2016

Further examination of randomized clinical trial data suggests that thiazide diuretics to treat hypertension may be associated with lower risk of hip and pelvic fractures compared with some other antihypertensive medications, according to an article published online by JAMA Internal Medicine.

Joshua I. Barzilay, M.D., of Kaiser Permanente of Georgia, Atlanta, and coauthors examined the effects of major classes of blood pressure-lowering medications on the incidence of hospitalization for hip and pelvic fractures.

The authors used Veterans Affairs and Medicare claims data along with data from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a large study that compared different antihypertensive therapies to prevent fatal coronary heart disease or nonfatal heart attacks and other cardiovascular disease outcomes.

The study reports a 21 percent lower risk of hip and pelvic fractures associated with the thiazide-type diuretic chlorthalidone compared with either lisinopril (an angiotensin-converting enzyme inhibitor) or amlodipine (a calcium channel blocker).

The analyses included 22,180 participants followed for up to eight years and, after the trial was completed, 16,622 participants were followed for up to an additional five years because claims data were available for them. There were 646 hip and pelvic fractures in trial plus post trial follow-up.

In further analyses that include trial and post-trial follow-up, the fracture risk was lower in the chlorthalidone group compared with the other treatment groups, although it was not statistically significant, according to the results. During the post-trial period, the study protocol no longer constrained the choice of blood pressure medication.

The authors note several study limitations including that analyses were conducted after the trial and that the present analyses relied on databases for fracture occurrence rather than medical records.

"The present results of short-term and long-term fracture protection with thiazide antihypertensive therapy compared with other antihypertensive medications strongly recommend use of a thiazide for hypertension treatment in addition to its long track record of cardiovascular protection," the study concludes.
-end-
(JAMA Intern Med. Published online November 21, 2016. doi:10.1001/jamainternmed.2016.6821; available pre-embargo at the For The Media website.)

Editor's Note: The article contains conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

The JAMA Network Journals

Related Blood Pressure Articles:

Do you really have high blood pressure?
A study by researchers at the University of Montreal Hospital Research Centre (CRCHUM) shows that more than half of family doctors in Canada are still using manual devices to measure blood pressure, a dated technology that often leads to misdiagnosis.
Why do we develop high blood pressure?
Abnormally high blood pressure, or hypertension, may be related to changes in brain activity and blood flow early in life.
For some, high blood pressure associated with better survival
Patients with both type 2 diabetes and acute heart failure face a significantly lower risk of death but a higher risk of heart failure-related hospitalizations if they had high systolic blood pressure on discharge from the hospital compared to those with normal blood pressure, according to a study scheduled for presentation at the American College of Cardiology's 66th Annual Scientific Session.
$9.4 million grant helps scientists explore how cell death from high blood pressure fuels even higher pressure
It's been known for decades that a bacterial infection can raise your blood pressure short term, but now scientists are putting together the pieces of how our own dying cells can fuel chronically high, destructive pressure.
Blood pressure diet improves gout blood marker
A diet rich in fruits, vegetables, low-fat dairy and reduced in fats and saturated fats (the DASH diet), designed decades ago to reduce high blood pressure, also appears to significantly lower uric acid, the causative agent of gout.
New tool to improve blood pressure measurement
Oxford University researchers have developed a prediction model that uses three separate blood pressure readings taken in a single consultation and basic patient characteristics to give an adjusted blood pressure reading that is significantly more accurate than existing models for identifying hypertension.
Blood vessels sprout under pressure
It is blood pressure that drives the opening of small capillaries during angiogenesis.
Better blood pressure control -- by mobile phone
An interactive web system with the help of your mobile phone can be an effective tool for better blood pressure control.
Time to reassess blood-pressure goals
High blood pressure or hypertension is a major health problem that affects more than 70 million people in the US, and over one billion worldwide.
With help from pharmacists, better blood pressure costs $22
A pharmacist-physician collaboration in primary-care offices effectively and inexpensively improved patients' high blood pressure.

Related Blood Pressure Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...